Immunogenicity and early clinical outcome after two or three doses of SARS-CoV-2 mRNA-BNT162b2 vaccine in actively treated cancer patients: results from the prospective observational Vax-On-Third study
在接受积极治疗的癌症患者中,接种两剂或三剂SARS-CoV-2 mRNA-BNT162b2疫苗后的免疫原性和早期临床结果:来自前瞻性观察性Vax-On-Third研究的结果
期刊:Annals of Oncology
影响因子:65.4
doi:10.1016/j.annonc.2022.04.002
Nelli, F; Giannarelli, D; Fabbri, A; Silvestri, M A; Berrios, J R Giron; Virtuoso, A; Marrucci, E; Schirripa, M; Mazzotta, M; Onorato, A; Panichi, V; Topini, G; Pessina, G; Natoni, F; Signorelli, C; Chilelli, M G; Primi, F; Ruggeri, E M